Inovio Pharmaceuticals has signed an agreement with German contract manufacturer Richter-Helm BioLogics for large-scale production of Covid-19 DNA vaccine candidate, INO-4800.
The deal, partially funded by a $1.3m initial grant from the Coalition for Epidemic Preparedness Innovations (CEPI), includes a total of $17.2m support for INO-4800 development.
Richter-Helm BioLogics has been manufacturing Inovio’s other DNA drug candidate VGX-3100 has been in manufacture since 2014, which is currently in Phase III clinical trials to treat precancerous cervical dysplasia caused by high-risk human papillomavirus (HPV).
Inovio commercial-scale plasmid manufacturing at Richter-Helm BioLogics for its DNA medicines platform. The aim is to manufacture